linjc16/ctgov huggingface dataset:
Clinical and Paraclinical Characteristics of Severe Bronchiolitis in Children From 2 Months to 12 Months at the Children's Hospital 1 in Ho Chi Minh City - Vietnam

Study Overview
=================
Brief Summary
-----------------
Goal: The aim of this study is to determine the epidemiological, clinical, paraclinical characteristics and treatment of severe bronchiolitis at the Children Hospital N01 in 2001-2002. Materials and method: in this cross-sectional study, specimens of 51 patients with severe bronchiolitis at the Children Hospital N01 from March, 1 st 2001 to February, 28th 2002 are described and analyzed.

Official Title
-----------------
Clinical and Paraclinical Characteristics of Severe Bronchiolitis in Children From 2 Months to 12 Months at the Children's Hospital 1 in Ho Chi Minh City - Vietnam

Conditions
-----------------
Epidemiological, Clinical, Paraclinical Characterictics of Severe Bronchiolitis

Intervention / Treatment
-----------------
* Biological: severe bronchiolitis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children younger from 2-12 months present fever (usually ≤38.3ºC [101ºF]) ,cough, and respiratory distress (eg, increased respiratory rate, retractions, wheezing, crackles) preceded by a one- to three-day history of upper respiratory tract symptoms (eg, nasal congestion and/or discharge) ] Respiratory distress. Exclusion Criteria: refusal to give informed consent mucus sample Barlett <=0

Ages Eligible for Study
-----------------
Minimum Age: 2 Months
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| mild to moderate bronchiolitis<br>Bronchiolistis patients without Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks, Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency and Neurologic disease | Biological: severe bronchiolitis<br>* Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks,Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency, Neurologic disease<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with Severe bronchiolitis at the Children Hospital N01 | Bronchiolitis in infants with: Preterm birth : gestational age < 37 weeks Respiratory failure: Irritable condition Breath rate > 50 per minute Hypoxiemia: SpO2 < 94% Poor feeding Hemodynamically significant congenital heart disease (congennital heart failure, moderate to severe pulmonary hypertension or cyanotic heart disease) | 2 years |
Effect Of The Consumption Of Fermented Dairy Drink On Common Infections In Shift-Workers

Study Overview
=================
Brief Summary
-----------------
This clinical study plans to investigate the effect of the consumption of a fermented dairy drink on the occurrence of common infections. This study will be performed in a healthy adult population of shift workers.

Official Title
-----------------
EFFECT OF THE CONSUMPTION OF FERMENTED DAIRY DRINK ON COMMON INFECTIONS IN SHIFT-WORKERS

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: fermented dairy product
* Other: non fermented dairy product


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male/female subjects aged 18 to 65 years (bounds included) Healthy subjects. Subjects working in two- or three-shift work including night work Exclusion Criteria: Subject with any food allergy Subject in a situation that, in the investigator opinion, could interfere with optimal participation in the present study or could constitute a special risk for the subject.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>fermented dairy product | Other: fermented dairy product<br>* fermented dairy product (2 bottles/day during 16 weeks)<br>|
| Placebo Comparator: 2<br>non fermented acidified dairy product. | Other: non fermented dairy product<br>* non fermented dairy product (2 bottles/day during 16 weeks)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of common infectious diseases during the 16 weeks of study product consumption |  | 0-16 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean duration of common infectious diseases during the 16 weeks of study product consumption. |  | 0-16 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Shiftworkers, volunteers
Microparticle Generation After Laparoscopic Surgical Treatment for Endometrioma.

Study Overview
=================
Brief Summary
-----------------
Study objective: To evaluate serial generation of microparticles (MPs) after laparoscopic stripping or CO2 laser vaporization in surgical treatment of patients with ovarian endometrioma (OE). Design: A prospective, randomized, blinded, pilot study, including 33 patients. Setting: Tertiary university hospital from April 2015 to June 2017. Patients: 33 women with unilateral OE undergoing laparoscopic surgery. Intervention: Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE. Measurements and Main results: Blood samples were collected before surgery, and at 2 hours, 24 hours, 1 month, and 3 months after surgery. MPs generation curve after ovarian endometrioma surgery was performed.

Official Title
-----------------
Microparticle Generation After Laparoscopic Surgical Treatment for Endometrioma: a Pilot, Prospective, Randomized Study Comparing Stripping With CO2 Laser Vaporization

Conditions
-----------------
Microparticle, Endometriosis, Laparoscopy

Intervention / Treatment
-----------------
* Procedure: Stripping versus laser CO2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 18 and 40 years and unilateral symptomatic OEs ≥3 cm. Exclusion Criteria: previous pelvic surgery, history of cancer, suspected malignancy, presurgical suspicion or evidence of deep endometriosis, presurgical suspicion or evidence of premature ovarian failure, and the use of estrogen suppressive drugs, including oral contraceptives, GnRH-agonists, progestins, or danazol in the preceding 3 months. We excluded patients with suspicion of deep endometriosis according to an extensive preoperative work-up (including magnetic resonance imaging when necessary) routinely performed in such patients.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Laparoscopic stripping ovarian endometriomas<br> | Procedure: Stripping versus laser CO2<br>* Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE.<br>|
| Active Comparator: Laser CO2 treatment ovarian endometriomas<br> | Procedure: Stripping versus laser CO2<br>* Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microparticle levels after two laparoscopic treatments of ovarian endometriomas |  | 1 month |
Sleep Plus Eating Routines for Weight Loss

Study Overview
=================
Brief Summary
-----------------
The present study will test the effectiveness of two different approaches for preparing overweight/obese individuals for weight loss: 1)providing important information about weight control, including dispelling common myths; or 2) developing a consistent sleep and eating routine to prepare for the challenges of a weight control intervention.

Official Title
-----------------
Increasing Sleep Duration: A Novel Approach to Weight Control. Study 5-Randomized Trial of Sleep Plus Eating Routines as An Approach to Prepare Participants for Weight Loss

Conditions
-----------------
Overweight and Obesity

Intervention / Treatment
-----------------
* Behavioral: Weight Loss Education
* Behavioral: Sleep and Eating Routine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 21 to 65 BMI 25 to 45 sleep 7 hours or less most nights Exclusion Criteria: use of medications affecting sleep sleep apnea shift work

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Weight Loss Education<br>Provides participants with important information about weight control and healthy eating prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes. | Behavioral: Weight Loss Education<br> <br> |
| Active Comparator: Sleep and Eating Routine<br>Establish a consistent sleep and eating routine prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes. | Behavioral: Sleep and Eating Routine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight |  | 20 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Executive Control | Executive control is measured by a variety of computer assessments. These include Go-No Go, delayed discounting, and perseverence as measured by mirror tracing and a hand grip task. | 4 and 20 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Weight loss
MRI Imaging of Labeled Human Islets Transplanted Into the Liver

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine whether human islets labeled by iron contrast agents could be imaged using magnetic resonance after transplantation into the liver of Type 1 diabetic recipients.

Detailed Description
-----------------
Islet transplantation represents approved therapeutic approach in selected Type 1 diabetic recipients with syndrome of hypoglycaemia unawareness. Existing imaging methods are not sufficient to provide adequate information about amount and fate of islets transplanted into the liver. Labeling of islets with superparamagnetic contrast agent ferucarbotran significantly shortens T2 relaxing time and therefore increase the contrast between islets and liver tissue in magnetic resonance imaging. In consequence, islets transplanted into liver could be easily detectable like hypotensive areas dispersed throughout the liver. MRI examination will be done on 1, 2, 4 weeks and 3, 6 and 12 months.

Official Title
-----------------
Phase 1 Study to Test Safety and Efficacy of Magnetic Resonance Imaging of Human Labeled Islets Transplanted Into the Liver in Type 1 Diabetic Recipients

Conditions
-----------------
Type 1 Diabetes Mellitus

Intervention / Treatment
-----------------
* Other: Transplantation of labeled islets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 1 diabetes mellitus normal renal parameters hypoglycaemia unawareness or rapid progression of diabetic retinopathy or neuropathy Exclusion Criteria: acute and chronic liver disease malignancy acute infection serious cardiovascular disease coagulopathy portal hypertension presence of metal protesis, cardio-stimulators, or other metal material in the body

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Labeled islets<br>Type 1 diabetic recipients after islet transplantation with islets labeled by iron contrast agent | Other: Transplantation of labeled islets<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of safety and efficacy of MRI imaging of transplanted human labeled islets |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
islet transplantation, magnetic resonance, Type 1 DM
Gait, Stair Climbing and Postural Stability in Knee Osteoarthritis Patients After Hyaluronic Acid Injection

Study Overview
=================
Brief Summary
-----------------
Treatment: five intro-articular Hyaluronic Acid injection Assessment has two parts, that are as follow: Postural stability and risk of fall assessment using Biodex stability index and Timed up and Go test Gait and stair climbing assessment using Vicon motion capture system synchronized with four force plates. For knee OA subjects, assessment was done in week one or before injection; and for healthy controls one assessment was performed.

Detailed Description
-----------------
This study aimed to assess the effect of hyaluronic acid injection on Postural stability, biomechanics of gait and stair climbing in individuals with bilateral knee osteoarthritis (OA). Participants were individuals with knee OA (control and treatment) and healthy people.

Conditions
-----------------
Bilateral Knee Osteoarthritis

Intervention / Treatment
-----------------
* Other: Hyaluronic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mild and moderate bilateral knee osteoarthritis Age between 50 and 70 years Exclusion Criteria: Recent Lower limb injury Diabetic Knee or hip replacement Knees HA injection in last 6 months Any neuromuscular disease such as stroke and Parkinson

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: biomechanis knee OA and HA injection<br>Weekly intra- articular Hyaluronic acid injection (20 MG/ 2 ML) into both knees for five weeks | Other: Hyaluronic acid<br>* treatment: Weekly intra-articular hyaluronic acid injection (20 MG / 2ML) into both knees for five weeks.<br>* Other names: Manufacturer: Fidia Pharmaceutici S.p.A, Italy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Postural stability after treatment |  | baseline and 6 weeks | 
| Changes in Biomechanics of gait after treatment |  | baseline and 6 weeks | 
| Changes in biomechanics of stair climbing after treatment |  | baseline and 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Pain after treatment |  | baseline and 6 weeks | 
| Changes in WOMAC scores after treatment |  | baseline and 6 weeks |
The Clinical Characteristics, Management and Prognosis of Patients Developing Intraoperative Cardiac Arrest During Transcatheter Aortic Valve Implantation

Study Overview
=================
Brief Summary
-----------------
This study was aimed to investigate the clinical characteristics, management and prognosis of patients developing intraoperative cardiac arrest during transcatheter aortic valve implantation

Official Title
-----------------
The Clinical Characteristics, Management and Prognosis of Patients Developing Intraoperative Cardiac Arrest During Transcatheter Aortic Valve Implantation

Conditions
-----------------
Cardiac Arrest, Transcatheter Aortic Valve Implantation

Intervention / Treatment
-----------------
* Other: follow up and record


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who developed intraoperative cardiac arrest during transcatheter aortic valve implantation from January 2014 to May 2019 - Exclusion Criteria: None. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients developing CA<br>Including patients developing intraoperative cardiac arrest during transcatheter aortic valve implantation from January 2014 to May 2019 | Other: follow up and record<br>* None additional intervention was applied to the subjects.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | In-hospital mortality | 1month |
Efficacy of Gastric Biopsy for Culture and Antibiotic Sensitivity Assessment

Study Overview
=================
Brief Summary
-----------------
Gastric biopsies will be taken to compare different methods of H.pylori disclosure.Standard methods will be compared to culture.

Official Title
-----------------
Efficacy of Gastric Biopsy for Culture and Antibiotic Sensitivity Assessment and Comparing of Different Methods for Helicobacter Pylori Disclosure

Conditions
-----------------
Other Diseases or Conditions | Patient

Intervention / Treatment
-----------------
* Procedure: Gastroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all referred for gastroscopy with clinical or endoscopic signs of peptic disease Exclusion Criteria: coagulation disorders pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Gastroscopy|The reason for gastroscopy will be not related to the study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Peptic disease, Helicobacter pylori, Different methods
Outcomes of Antipsychotic Medication Used in the Emergency Department

Study Overview
=================
Brief Summary
-----------------
To review records of patients treated with antipsychotics (including Adasuve, Geodon, Haldol) in order to evaluate outcomes.

Detailed Description
-----------------
A retrospective chart review will be performed for all patients presenting to the ED with agitation and subsequently given antipsychotic therapy for treatment. Identification of patients will be through chart review of patients presenting with agitation. Data to be recorded include patient age, gender, medical history, time of presentation, time of treatment, co morbidities, use of restraint, time to disposition and patient outcome. Inclusion criteria include all patients over age 18 presenting to the ED with agitation and treated with antipsychotics. No patients will be knowingly excluded from analysis. We will compare resulting outcomes of patients treated for agitation to see if Adasuve is superior to other commonly prescribed antipsychotics through its rate of discharge home and overall time in the emergency department.

Official Title
-----------------
Outcomes of Antipsychotic Medication Use in the Emergency Department: A Retrospective Comparison Study

Conditions
-----------------
Agitation,Psychomotor

Intervention / Treatment
-----------------
* Drug: Adasuve
* Drug: Alternative medications


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients given antipsychotic therapy for acute agitation Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Adasuve|Inhaled medication to treat acute agitation in the emergency department|
|Drug: Alternative medications|Medication given to treat acute agitation in the emergency department|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of stay in the emergency department | We will compare resulting outcomes of patients treated for agitation to see if Adasuve is superior to other commonly prescribed antipsychotics through its rate of discharge home and overall time in the emergency department. | Participants will be followed for the duration of emergency department stay, an expected average of 12 hours. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disposition | disposition (home, transfer, admit), and time to disposition | Participants will be followed for the duration of emergency department stay, an expected average of 12 hours. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
schizophrenia, Bipolar 1 disorder